drugset / Trial / NCT07116577
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
NaSingle-groupOpen-labelTreatment
Summary
This single-center, single-arm, prospective study plans to enroll patients with advanced colorectal cancer who have failed first-line or higher systemic therapies. Participants will receive a combination of iparomlimab and tuvonralimab (QL1706), trifluridine/tipiracil (TAS-102), bevacizumab, and palliative radiotherapy. The efficacy and safety of this combination therapy will be evaluated by assessing objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety profile.
Timeline
- Start
- 2025-08-31
- Primary completion
- 2027-08-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Iparomlimab | Monoclonal antibody | — | Intravenous |
| Subject | TAS-102 | Small molecule | 35 mg/m2 | Oral |
| Subject | Tuvonralimab | Monoclonal antibody | — | Intravenous |